Want to see POM full AI Analyst Report?
POM Stock Chart & Stats
$0.31
--
Market closed
$0.31
--
Day’s Range― - ―
52-Week Range$0.50 - $115.74
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.20M
Market Cap
$6.53M
Enterprise Value$505.22M
Total Cash (Recent Filing)$2.11B
Total Debt (Recent Filing)$37.66B
Price to Earnings (P/E)―
Beta2.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,774,573
10 Day Avg. Volume781,994
30 Day Avg. Volume2,198,746
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-4.75
Price to Sales (P/S)5.39
P/FCF Ratio-14.43
Enterprise Value/Market Cap77.40
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue has grown steadily through 2022–2025 with 2025 up ~17% YoY, showing the company can expand user adoption and sales at scale. Durable top-line growth provides a platform for monetization, partnerships and incremental investment in AI and services if financing is available.
AI-driven Integrated Platform (healthcare Flywheel)Management’s flywheel strategy targets compounding data assets and network effects by linking wearables, AI, clinicians and payors. If executed, this creates a durable competitive barrier and scalable predictive-health infrastructure that strengthens long-term differentiation.
Diversified, Recurring Revenue RoadmapShifting from single-product/pharmacy reliance to subscriptions, B2B offerings and data services targets higher-margin, recurring revenue. Structural diversification can stabilize cash flows over time and enable commercialization of AI and real-world data assets.
Bears Say
Negative Equity And Rising LeverageNegative equity and increasing debt materially weaken financial flexibility and heighten solvency and refinancing risk. This structural balance-sheet stress constrains the company’s ability to invest, absorb shocks or execute long-term platform expansion without dilution or onerous financing.
Sharply Worsening Cash BurnPersistent negative operating and free cash flow with a large 2025 step-up in burn raises structural funding risk. Continued cash deficits will necessitate recurring external financing, increasing dilution or leverage and potentially limiting investment in product, data acquisition or partnerships.
Low Gross Margins And Widening Losses Despite GrowthTop-line growth has not translated into profit: compressed gross margins and a larger net loss reflect weak unit economics and rising opex (including heavy R&D and IPO costs). Structural margin weakness challenges sustainable profitability even as revenue scales.
PomDoctor Ltd. Unsponsored ADR News
POM FAQ
What was PomDoctor Ltd. Unsponsored ADR’s price range in the past 12 months?
PomDoctor Ltd. Unsponsored ADR lowest stock price was $0.50 and its highest was $115.74 in the past 12 months.
What is PomDoctor Ltd. Unsponsored ADR’s market cap?
PomDoctor Ltd. Unsponsored ADR’s market cap is $6.53M.
When is PomDoctor Ltd. Unsponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PomDoctor Ltd. Unsponsored ADR’s earnings last quarter?
Currently, no data Available
Is PomDoctor Ltd. Unsponsored ADR overvalued?
According to Wall Street analysts PomDoctor Ltd. Unsponsored ADR’s price is currently Overvalued.
Does PomDoctor Ltd. Unsponsored ADR pay dividends?
PomDoctor Ltd. Unsponsored ADR does not currently pay dividends.
What is PomDoctor Ltd. Unsponsored ADR’s EPS estimate?
PomDoctor Ltd. Unsponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PomDoctor Ltd. Unsponsored ADR have?
PomDoctor Ltd. Unsponsored ADR has 6,774,573 shares outstanding.
What happened to PomDoctor Ltd. Unsponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PomDoctor Ltd. Unsponsored ADR?
Currently, no hedge funds are holding shares in POM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PomDoctor Ltd. Unsponsored ADR
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.17% Other Institutional Investors
99.83% Public Companies and
Individual Investors